PLoS ONE (Jan 2022)

B-cell activating factor (BAFF) and its receptors' expression in pediatric nephrotic syndrome is associated with worse prognosis.

  • Jessica Forero-Delgadillo,
  • Vanessa Ochoa,
  • Jaime M Restrepo,
  • Laura Torres-Canchala,
  • Ivana Nieto-Aristizábal,
  • Ingrid Ruiz-Ordoñez,
  • Aura Sánchez,
  • María Claudia Barrera,
  • Carlos Andrés Jimenez,
  • Gabriel J Tobón

DOI
https://doi.org/10.1371/journal.pone.0277800
Journal volume & issue
Vol. 17, no. 11
p. e0277800

Abstract

Read online

AimImmune pathogenesis of nephrotic syndrome (NS) is not completely understood. We aimed to evaluate the expression of B-cell activating factor (BAFF) and its receptors in renal samples from pediatric NS patients and its relationship with renal function survival.Materials and methodsWe conducted an ambispective study on 33 patients with pediatric NS. Immunohistochemistry for BAFF, TACI, BCMA and BR3 was performed. Markers were evaluated on podocytes and interstitial inflammatory infiltrates (III). We performed Kaplan-Meier curves to describe renal function survival according to markers' expression.ResultsThirty-three NS patients were included. Minimal change disease was seen in 21 (63.6%) patients, and focal segmental glomerulosclerosis in 12 (36.4%). BAFF was found in podocytes (18.2% of samples) and III (36.4% of samples), BAFF-R in one sample, TACI in 4 (podocytes and III), and BCMA in 5 samples of podocytes and 7 of III. BAFF on podocytes and III was associated with worst renal function at follow-up; those patients had 25% probability of having GFR >90 mL/min/1.73m2, versus 84.9% when absent (p = 0.0067). Patients with BAFF in III had 42.9% probability of having GFR>90 mL/min/1.73 m2, versus 94.1% when absent (p = 0.0063).ConclusionBAFF expression in renal biopsies could be a prognostic factor for renal function.